2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Review slidesets and expert analyses of key data from the 2020 Hematology Virtual Annual Meeting!
Jeremy S. Abramson, MD, MMSc
Hanny Al-Samkari, MD
John M. Burke, MD
Jorge Cortes, MD
Amy E. DeZern, MD, MHS
Shaji K. Kumar, MD
Sagar Lonial, MD
Mark A. Schroeder, MD
Jeff P. Sharman, MD
Sujit Sheth, MD
Srdan Verstovsek, MD, PhD
Eunice S. Wang, MD

Acute and Chronic Leukemias

Expert faculty review and share their insights and perspectives on key studies on the management of acute and chronic leukemias presented at the virtual Hematology 2020 annual meeting.

Jorge Cortes, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: February 12, 2021 Expired: February 11, 2022

In this commentary, 2 experts discuss their top presentation choices from ASH 2020 in acute and chronic leukemias with the most potential to impact practice.

Jorge Cortes, MD Eunice S. Wang, MD Released: March 3, 2021

Experts discuss results and implications from 3 of the key studies in acute myeloid leukemia and chronic myeloid leukemia from the virtual Hematology 2020 meeting, including magrolimab in AML, the STAMP inhibitor asciminib in CML (the ASCEMBL trial), and optimal dosing for ponatinib in CML (the OPTIC trial).

Jorge Cortes, MD Eunice S. Wang, MD Released: February 26, 2021

Lymphomas and Chronic Lymphocytic Leukemia

Review expert perspectives on the most clinically relevant data on indolent and aggressive lymphomas presented at the 2020 ASH annual meeting.

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 26, 2021 Expired: February 25, 2022

In this commentary, Jeremy S. Abramson, MD, MMSc, discusses the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.

Jeremy S. Abramson, MD, MMSc Released: March 11, 2021

Listen to Jeremy S. Abramson, MD, MMSc, discuss the presentations from ASH 2020 that he expects to affect practice in the management of patients with lymphomas/CLL.

Jeremy S. Abramson, MD, MMSc Released: March 26, 2021

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Review expert perspectives on the most clinically relevant data on myelodysplastic syndromes and myeloproliferative neoplasms presented at the 2020 ASH annual meeting.

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 16, 2021 Expired: February 15, 2022

In this commentary, 2 experts discuss their top presentation choices at ASH 2020 in MDS and MPNs with the most potential to impact clinical practice.

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Released: February 23, 2021

In this podcast episode, listen to Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, PhD, discuss new data and studies in MDS and MPNs presented at ASH 2020.

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Released: February 5, 2021

Multiple Myeloma

Expert faculty review and share their insights and perspectives on key findings in multiple myeloma from ASH 2020.

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: March 22, 2021 Expired: March 21, 2022

In this commentary, 2 experts discuss their top presentation choices at ASH 2020 in myeloma with the most potential to impact clinical practice.

Shaji K. Kumar, MD Sagar Lonial, MD Released: March 8, 2021

Two experts discuss results from key studies in multiple myeloma from the virtual Hematology 2020 meeting, including updated data on treatment options for newly diagnosed disease and an analysis of available agents for relapsed/refractory myeloma.

Shaji K. Kumar, MD Sagar Lonial, MD Released: March 12, 2021

Nonmalignant Hematology

Review expert perspectives and insights on the most clinically relevant data on ITP, hemophilia, β-thalassemia, sickle cell disease, and GVHD presented at the Hematology 2020 annual meeting.

Hanny Al-Samkari, MD Mark A. Schroeder, MD Sujit Sheth, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 11, 2021 Expired: February 10, 2022

In this commentary, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, share their top choices of new data presented at ASH 2020 in nonmalignant hematologic diseases, including studies on disorders of bleeding and clotting, hemoglobinopathies, and GVHD.

Hanny Al-Samkari, MD Mark A. Schroeder, MD Sujit Sheth, MD Released: February 24, 2021

In this podcast episode, listen to Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, discuss their takeaways on new data presented at ASH 2020 in nonmalignant hematologic diseases, including studies on disorders of bleeding and clotting, hemoglobinopathies, and GVHD.

Hanny Al-Samkari, MD Mark A. Schroeder, MD Sujit Sheth, MD Released: February 10, 2021

ClinicalThought: Conference Preview

Review experts' perspectives on the most clinically relevant data on malignant and nonmalignant hematology results to be presented at the ASH 2020 annual meeting, including key insights and the latest data you need to understand and integrate into your practice.

Hanny Al-Samkari, MD John M. Burke, MD Jorge Cortes, MD Amy E. DeZern, MD, MHS Shaji K. Kumar, MD Sagar Lonial, MD Mark A. Schroeder, MD Jeff P. Sharman, MD Sujit Sheth, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 2, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue